Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Matrices
Reexamination Certificate
2011-03-01
2011-03-01
Tran, S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Matrices
C464S062100, C464S062100, C464S062100
Reexamination Certificate
active
07897175
ABSTRACT:
A dosage form comprises (1) a solid amorphous dispersion comprising a cholesterol ester transfer protein inhibitor and an acidic concentration-enhancing polymer and (2) an HMG-CoA reductase inhibitor. The solid amorphous dispersion and the HMG-CoA reductase inhibitor are combined in the dosage form so that the solid amorphous dispersion and the HMG-CoA reductase inhibitor are substantially separate from one another in the dosage form.
REFERENCES:
patent: 5180589 (1993-01-01), Joshi et al.
patent: 5932587 (1999-08-01), Schmeck et al.
patent: 5935939 (1999-08-01), Kararli et al.
patent: 6004582 (1999-12-01), Faour et al.
patent: 6126971 (2000-10-01), Mills et al.
patent: 6197786 (2001-03-01), DeNinno et al.
patent: 6235311 (2001-05-01), Ullah et al.
patent: 6310075 (2001-10-01), DeNinno et al.
patent: 6548555 (2003-04-01), Curatolo et al.
patent: 6620821 (2003-09-01), Robl
patent: 7115279 (2006-10-01), Curatolo et al.
patent: 2002/0077348 (2002-06-01), Dean et al.
patent: 2004/0132771 (2004-07-01), Babcock et al.
patent: 2004/0185102 (2004-09-01), Friesen et al.
patent: 1027888 (2000-08-01), None
patent: WO 9638153 (1996-12-01), None
patent: WO 00/35425 (2000-06-01), None
patent: WO 0038722 (2000-07-01), None
patent: WO0038722 (2000-07-01), None
patent: WO 01/93860 (2001-12-01), None
patent: WO 02/13797 (2002-02-01), None
patent: WO 0211710 (2002-02-01), None
patent: WO 0213797 (2002-02-01), None
patent: WO 02100394 (2002-12-01), None
Remington: The Science and Practice of Pharmacy, 19thEdition, (1995).
Serajuddin, A. T. M., et al., Selection of Solid Dosage Form Composition through Drug-Excipient Compatibility Testing,Journal of Pharmaceutical Sciences, vol. 88, No. 7, pp. 696-704, (Jul. 1999).
Bauer, K. H., et al., Lehrbuch der Pharmazeutischen Technologie,Wissenschaftliche Verlaosoesellschaft MBH, pp. 131-326 (1999).
Gennaro, A.R., Remington: The Science and Practice of Pharmacy 20thed., Chapter 45, pp. 858-861, Lippincott Williams and Wilkins, Baltimore, Maryland, 2000.
Lachman, L., et al., The Theory and Practice of Industrial Pharmacy, 3rded., pp. 330-331, Lea & Febiger, Philadelphia, Pennsylvania, 1986.
Cole, G, Pharmaceutical Coating Technology, Chapter 1, p. 2, Taylor and Francis, Bristol, Pennsylvania, 1995.
Medicines Compendium 2002, “Zocor,” pp. 2202-2204, Datapharm Communications Ltd., 2002.
Full Prescribing Information: Zocor (simvastatin), pp. 10-11.
Lieberman, H.A., et al., Pharmaceutical Dosage Forms, 2nded,—Tablets, vol. 1, pp. 90-91, lnforma Healthcare, New York, New York, 1989.
Bauer,K., et al, Lehrbuch der Pharmazeutischen Technologie, Chapter 23, Wissenschaftliche Verlagsgesellschaft mgh, Stuttgarg, 1999.
Lieberman, H.A., et al., Pharmaceutical Dosage Forms, 2nded, Tablets, vol. 1, pp. 131-132 and pp. 179-181, Informa Healthcare, New York, New York, 1989.
Hatanaka, T., “Clinical Pharmacokinetics of Pravastatin—Mechanisms of Pharmacokinetic Events,” Clin. Pharmacokinet., vol. 39, No. 6, pp. 397-412, 2000.
Friesen Dwayne T.
Hancock Bruno C.
Lorenz Douglas A.
Lyon David K.
McDermott Timothy J.
Bend Research Inc.
Chernoff Vilhauer & McClung & Stenzel
Tran S.
LandOfFree
Dosage forms comprising a CETP inhibitors and an HMG-CoA... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dosage forms comprising a CETP inhibitors and an HMG-CoA..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dosage forms comprising a CETP inhibitors and an HMG-CoA... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2776586